Bimzelx (bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa – UCB
UCB announced long-term data from the BE HEARD trials for Bimzelx (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, building on the established efficacy profile… read more.




